In a change from last month, some good news occurred for Pfizer in the multifaceted litigation over its Neurontin epilepsy drug.
Last summer, when plaintiffs’ lawyers in the federal multidistrict litigation over suicide risks associated with Neurontin voluntarily dismissed dozens of product liability cases, The American Lawyer called the litigation “the incredible, shrinking mass tort.” On Friday, that became truer than ever. Boston federal Magistrate Judge Leo Sorokin recommended tossing the bulk of the remaining cases in the MDL-a whopping 190 suits-as a sanction against a plaintiffs’ lawyer who filed more cases than anyone else in the litigation.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
